biglycan


Also found in: Financial, Wikipedia.

bi·gly·can

(bī'glī-kan), [MIM*301870]
A small interstitial proteoglycan that contains two glycosaminoglycan chains.
Synonym(s): proteoglycan I

biglycan

A small leucine-rich repeat (LRR) proteoglycan encoded by BGN on chromosome Xq28, which plays a role in assembly of collagen fibrils and muscle regeneration. It interacts with alpha-dystroglycan, alpha- and gamma-sarcoglycan and collagen VI, and it is critical for the assembly of the dystrophin-associated protein complex.

biglycan

a small chondroitin sulfate proteoglycan found in mineralized bone.
References in periodicals archive ?
2) The cartilage tissue of the patients with osteoarthritis and rheumatoid arthritis include biglycan fragments obtained due to breakdown of proteoglycans by ADAMTSs.
They also found significant increased mRNA expression of extracellular matrix proteins biglycan and decorin and concluded that PRP appears to enhance the healing of meniscal defects.
The key protein Biglycan restores the muscle-strengthening presence of a protein called utrophin, which is normally prevalent only in very young children.
Candidate polysaccharide or proteoglycan subunits include aggrecan, agrin, bamacan, heparan sulfate, chondroitin sulfate, keratan sulfate, versican, phosphocan, perlecan, hyaluronan, decorin, dermatan sulfate, biglycan, fibromodulin, alginate, polylactate, polyglycolic acid, starch, dextran, agarose, chitan, chitosan, and heparin.
ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan.
Two sequence-specific peptide antisera (LF-15 and LF-30) generated against synthetic peptides corresponding to amino acids 11-24 and 5-17 of the human core proteins of 2 small leucine-rich proteoglycans, biglycan and decorin, were used to characterize territorial or interterritorial cartilage matrices.
Funding Supplements Tivorsan Pharmaceuticals' Commercialization Efforts of Biglycan as Novel Disease-Modifying Therapeutic
Each transcriptional factor then regulates its target genes such as E-cadherin, MMPs, integrin and biglycan leading to epithelial-mesenchymal transition (EMT), migration and invasion (Wu 2006).
Grant Funds Work of Tivorsan Pharmaceuticals' Team to Bring Recombinant Biglycan to the Clinic for the Possible Treatment of Duchenne Muscular Dystrophy
An industry expert panel affiliated with Windhover selected Tivorsan's Biglycan in the category of "Hot Space" therapeutic areas, inclusive of projects in Women's Health, Dermatology, Bone and Muscle Disease, Ophthalmology and other high value areas.
Food and Drug Administration (FDA) for a recombinant humanized form of biglycan as a potential muscular dystrophy treatment.
Study published in PNAS shows recombinant human biglycan reduces muscle damage and improves function in mouse model of DMD